参考文献/References:
[1] Colombo N,Peiretti M,Garbi A,et al.ESMO guidelines working group.non epithelial ovarian cancer:ESMO clinical practice guidelines for diagnosis,treatment and follow up [J].Ann Oncol,2012,23(Suppl 7):20-26.
[2] 程峰,朱笕青.卵巢癌减瘤术结局及病理分期与术前血细胞计数的关系[J].中国医师杂志,2017,19(1): 83-85.
[3] 赵谊宁,陶陶,张力杰,等.雌激素受体ERα及ERβ与肿瘤关系的研究进展[J].东南大学学报:医学版,2016,35(3):418-422.
[4] 黄海伟,谢虹,马新,等.miR-26b在卵巢癌组织中的表达水平及其与预后的关系[J].中国妇幼保健,2018,33(19):4507-4509.
[5] 陈诚,游雪云,付子毅.miR-26b在卵巢癌组织中的表达与功能[J].中国老年学杂志, 2017,37(1):15-17.
[6] 叶旭,李力.miRNA在卵巢癌早期诊断和预后中作用的研究进展[J].中国肿瘤生物治疗杂志,2019,26(6):715-719.
[7] 高瑶,邹霞,高军.miRNA在卵巢癌诊治及预后预测中作用的研究进展[J].山东医药,2019,59(3):87-90.
[8] Casimiro M C,Velasco-Velázquez M,Aguirre-Alvarado C,et al.Overview of cyclins D1 function in cancer and the CDK inhibitor landscape:past and present [J].Expert Opin Investig Drugs,2014,23(3):295-304.
[9] Kanter M,Turan G,Usta C,et al.Survivin and cycline D1 expressions are associated with malignant potential in mucinous ovarian neoplasms [J].J Mol Histol,2016,47(2):145-152.
[10] 胡观丽,张晶波,董洁,等.雌激素受体α、β及细胞周期蛋白D1、癌基因蛋白质P21在子宫内膜癌组织中的表达及临床意义[J].安徽医药,2019,23(9):1769-1773.
[11] Iwona K A,lina R,Anna F,et al.PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients [J].Cancer Biology&Therapy,2009,8(1):1-6.
[12] Chan K K,Leung T H,Chan D W,et al.Targeting estrogen receptor subtypes(ERα and ERβ)with selective ER modulators in ovarian cancer [J].J Endocrinol,2014,221(2):325-336.